Prediction of clinical response to drugs in ovarian cancer using the chemotherapy resistance test (CTR-test)

Table 4 Correlation of CTR-Test results and clinical response and comparison to Kern and Weisenthal data

	SR		MR		ER
	Resp. / n	% 95% CI	Resp. / n	% 95% CI	Resp. / n	% 95% CI
Total data set (Ovarian cancer) Charité Berlin 2012	22/28	79 59–92	9/17	53 28–77	0/7	0 0–41
Total data set Kern DH, Weisenthal LM (1990)	115/222	52 45–59	16/101	16 9–24	1/127	1 0–4
Ovarian cancer Kern DH, Weisenthal LM (1990)	14/24	58 37–78	0/11	0 0–28	0/11	0 0–28
Single agent chemotherapy Kern DH, Weisenthal LM (1990)	72/151	48 40–56	9/79	16 5–21	1/115	1 0–5
Single agent chemotherapy Charité Berlin 2012	4/9	44 14–79	2/6	33 4–78	0/4	0 0–60
Combination chemotherapy Kern DH, Weisenthal LM (1990)	43/71	61 48–72	7/22	32 14–55	0/12	0 0–26
Combination chemotherapy Charité Berlin 2012	18/19	95 74–100	7/11	64 31–89	0/3	0 0–71

The number of responders (Resp.) among the total number of patients (n) for the three different CTR-Test results are listed. The percentage and the 95% confidence interval (CI) are indicated
From Kern and Weisenthal 1990, the total data set, ovarian cancer, single agent and combination chemotherapy data are presented. From the Charité Berlin 2012 (see Table 3), the total data set, single agent and combination chemotherapy data are presented

ISSN: 1757-2215